Structural basis for thrombin activation of a protease-activated receptor: Inhibition of intramolecular liganding

Chemistry and Biology

Volumn 10, Issue 11, 2003, Pages 1033-1041

  Seeley, Stacy ^a,c   Covic, Lidija ^a,b   Jacques, Suzanne L ^a,b   Sudmeier, James ^a   Baleja, James D ^a   Kuliopulos, Athan ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c KETTERING UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RICKETTSIA SP. PAR;

EID: 0344668870     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2003.10.014     Document Type: Article

References (51)

1. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature. 407:2000;258-264.
2. Hollenberg M.D., Compton S.J. Proteinase-activated receptors. Pharmacol. Rev. 54:2002;203-217.
3. Vu T.-K.H., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor action. Cell. 64:1991;1057-1068.
4. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.W., Timmons C., Tram T., Coughlin S.R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature. 386:1997;502-506.
5. Cenac N., Coelho A.-M., Nguyen C., Compton S., Andrade-Gordon P., MacNaughton W.K., Wallace J.L., Hollenberg M.D., Bunnett N.W., Garcia-Villar R., et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 161:2002;1903-1915.
6. Xu W.-F., Andersen H., Whitmore T.E., Presnell S.R., Yee D.P., Ching A., Gilbert T., Davie E.W., Foster D.C. Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. USA. 95:1998;6642-6646.
7. Andrade-Gordon P., Derian C.K., Maryanoff B.E., Zhang H.-C., Addo M.F., Cheung W.-M., Damiano B.P., D'Andrea M.R., Darrow A.L., DeGaravilla L., et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298:2001;34-42.
8. Bahou W.H. Attacked from within, blood thins. Nat. Med. 8:2002;1082-1083.
9. Nelken N.A., Soifer S.J., O'Keefe J., Vu T.-K.H., Charo I.F., Coughlin S.R. Thrombin expression in normal and atherosclerotic human arteries. J. Clin. Invest. 90:1992;1614-1621.
10. Griffin C.T., Srinivasan Y., Zheng Y.-W., Huang W., Coughlin S.R. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 293:2001;1666-1670.
11. Even-Ram S., Uziely B., Cohen P., Grisaru-Granovsky S., Maoz M., Ginzburg Y., Reich R., Vlodavsky I., Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 4:1998;909-914.
12. Kamath L., Meydani A., Foss F., Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res. 61:2001;5933-5940.
13. Hollenberg M.D. Receptor binding and agonist efficacy. new insights from mutants of the thrombin protease-activated receptor-1 (PAR1) Mol. Pharmacol. 58:2000;1175-1177.
14. Cook J.J., Sitko G.R., Bednar B., Condra C., Mellot M.J., Feng D.-M., Nutt R.F., Shafer J.A., Gould R.J., Connolly T.M. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation. 91:1995;2961-2971.
15. Bernatowicz M.S., Klimas C.E., Hartl K.S., Peluso M., Allegretto N.J., Seiler S.M. Development of potent thrombin receptor antagonist peptides. J. Med. Chem. 39:1996;4879-4887.
16. Andrade-Gordon P., Maryanoff B.E., Derian C.K., Zhang H.-C., Addo M.F., Darrow A.L., Eckardt A.J., Hoekstra W.J., McComsey D.F., Oksenberg D., et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. USA. 96:1999;12257-12262.
17. Covic L., Gresser A.L., Talavera J., Swift S., Kuliopulos A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. USA. 99:2002;643-648.
18. Covic L., Misra M., Badar J., Singh C., Kuliopulos A. Pepducin-based intervention of thrombin receptor signaling and systemic platelet activation. Nat. Med. 8:2002;1161-1165.
19. Kuliopulos A., Covic L., Seeley S.K., Sheridan P.J., Helin J., Costello C.E. Plasmin desensitization of the PAR1 thrombin receptor. kinetics, sites of truncation, and implications for thrombolytic therapy Biochemistry. 38:1999;4572-4585.
20. Chen J., Ishii M., Wang L., Ishii K., Coughlin S.R. Thrombin receptor activation. J. Biol. Chem. 269:1994;16041-16045.
21. O'Brien P.J., Prevost N., Molino M., Hollinger M.K., Woolkalis M.J., Woulfe D.S., Brass L.F. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR. 1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J. Biol. Chem. 275:2000;13502-13509.
22. Scarborough R.M., Naughton M., Teng W., Hung D.T., Rose J., Vu T.-K.H., Wheaton V.I., Turck C.W., Coughlin S.R. Tethered ligand agonist peptides. J. Biol. Chem. 267:1992;13146-13149.
23. Bahou W.F., Coller B.S., Potter C.L., Norton K.J., Kutok J.L., Goligorsky M.S. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation. J. Clin. Invest. 91:1993;1405-1413.
24. Bahou W.F., Kutok J.L., Wong A., Potter C.L., Coller B.S. Identification of a novel thrombin receptor sequence required for activation-dependent responses. Blood. 84:1994;4195-4202.
25. Nanevicz T., Ishii M., Wang L., Chen M., Chen J., Turck C.W., Cohen F.E., Coughlin S.R. Mechanisms of thrombin receptor agonist specificity. J. Biol. Chem. 270:1995;21619-21625.
26. Blackhart B.D., Ruslim-Litrus L., Lu C.-C., Alves V.L., Teng W., Scarborough R.M., Reynolds E.E., Oksenberg D. Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol. Pharmacol. 58:2000;1178-1187.
27. Ji T.H., Grossmann M., Ji I. G protein-coupled receptors. I. diversity of receptor-ligand interactions J. Biol. Chem. 273:1998;17299-17302.
28. Gerszten R.E., Chen J., Ishii M., Ishii K., Wang L., Nanevicz T., Turck C.W., Vu T.-K.H., Coughlin S.T. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 368:1994;648-651.
29. Lerner D.J., Chen M., Tram T., Coughlin S.R. Agonist recognition by proteinase-activated receptor and thrombin receptor. J. Biol. Chem. 271:1996;13943-13947.
30. Al-Ani B., Saifeddine M., Kawabata A., Hollenberg M.D. Proteinase activated receptor 2. role of extracellular loop 2 for ligand-mediated activation Br. J. Pharmacol. 128:1999;1105-1113.
31. Compton S.J., Sandhu S., Wisjesuriya S.J., Hollenberg M.D. Glycosylation of human proteinase-activated receptor-2 (hPAR2). role in cell surface expression and signalling Biochem. J. 368:2002;495-505.
32. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Trong I.L., Teller D.C., Okada T., Stenkamp R.E., et al. Crystal structure of rhodopsin. A G protein-coupled receptor Science. 289:2000;739-745.
33. Rydel T.J., Ravichandran K.G., Tulinski A., Bode W., Huber R., Roitsch C., Fenton J.W. The structure of a complex of recombinant hirudin and human α-thrombin. Science. 249:1990;277-280.
34. Liu L.W., Vu T., Esmon C.T., Coughlin S.R. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J. Biol. Chem. 266:1991;16977-16980.
35. Vu T.-K.H., Wheaton V.I., Hung D.T., Charo I., Coughlin S.R. Domains specifying thrombin-receptor interaction. Nature. 353:1991;674-677.
36. Ishii K., Gerszten R., Zheng Y.W., Welsh J.B., Turck C.W., Coughlin S.R. Determinants of thrombin receptor cleavage. J. Biol. Chem. 270:1995;16435-16440.
37. Mathews I.I., Padmanabhan K.P., Ganesh V., Tulinsky A., Ishii M., Chen J., Turck C.E., Coughlin S.R., Fenton J.W. Crystallographic structures of thrombin complexes with thrombin receptor peptides. existence of expected and novel binding modes Biochemistry. 33:1994;3266-3279.
38. Jacques S., LeMasurier M., Sheridan P.J., Seeley S.K., Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor. enhancement of macromolecular association and cleavage J. Biol. Chem. 275:2000;40671-40678.
39. Ayala Y.M., Cantwell A.M., Rose T., Bush L.A., Arosio D., Cera E.D. Molecular mapping of thrombin-receptor interactions. Proteins. 45:2001;107-116.
40. Ahn H.-S., Foster C., Boykow G., Arik L., Smith-Torhan A., Hesk D., Chatterjee M. Binding of a thrombin receptor tethered ligand analogue to human platelet thrombin receptor. Mol. Pharmacol. 51:1997;350-356.
41. Matoukas J.M., Panagiotopoulos D., Keramida M., Mavromoustakos T., Yamdagni R., Wu Q., Moore G.J., Saifeddine M., Hollenberg M.D. Synthesis and contractile activities of cyclic thrombin receptor-derived peptide analogues with Phe-Leu-Leu-Arg motif. importance of the Phe/Arg relative conformation and the primary amino group for activity J. Med. Chem. 39:1996;3585-3591.
42. Jacques S., Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem. J. 376:2003;. in press.
43. Korepanova A., Douglas C., Leyngold I., Logan T.M. N-terminal extension changes the folding mechanism of the FK506-binding protein. Protein Sci. 10:2001;1905-1910.
44. Hammes S.R., Coughlin S.R. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells. evidence for a novel mechanism for preventing or terminating signaling by PAR1's tethered ligand Biochemistry. 38:1999;2486-2493.
45. 1a vassopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor. J. Biol. Chem. 272:1997;21027-21036.
46. Covic L., Gresser A.L., Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry. 39:2000;5458-5467.
47. Qui X., Padmanabhan K.P., Carperos V.E., Tulinsky A., Kline T., Maraganore J.M., Fenton J.W. Structure of the Hirulog 3 complex and nature of the S' subsites of substrates and inhibitors. Biochemistry. 31:1992;11689-11697.
48. Nakanishi-Matsui M., Zheng Y.-W., Sulciner D.J., Weiss E.J., Ludeman M.J., Coughlin S.R. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 404:2000;609-613.
49. Kuliopulos A., Walsh C.T. Production, purification, and cleavage of tandem repeats of recombinant peptides. J. Am. Chem. Soc. 116:1994;4599-4607.
50. Brünger A.T. X-PLOR. A System for X-Ray Crystallography and NMR:1987;Yale University Press, New Haven, CT.
51. Hsu-Lin S., Berman C.L., Furie B.C., August D., Furie B. A platelet membrane protein expressed during platelet activation and secretion. J. Biol. Chem. 259:1984;9121-9126.